文献速递妇科母胎医学

遗传性妇科癌症家系级联基因检测率低:改善癌症预防的机会

Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.
PubMed 文献 · Gynecol Oncol · 2019-11-25

该研究调查了2011至2016年间在某学术机构经胚系基因检测确诊的遗传性乳腺癌卵巢癌(HBOC)或林奇综合征(LS)患者,评估其向亲属告知检测结果及家系级联基因检测(CGT)的情况。结果显示,参与者向87%的一级亲属告知了结果,但仅40%的一级亲属接受了检测;女性一级亲属的CGT率显著高于男性(59% vs 21%,P < 0.001),HBOC患者报告的一级亲属CGT率高于LS患者(49% vs 33%,P = 0.02)。作者认为告知率虽高但CGT率低,存在性别和突变特异性障碍,未来需实施针对性材料以提高CGT率。

要点

  • 参与者向87%的一级亲属告知了基因检测结果,但仅40%的一级亲属接受了级联检测。
  • 女性一级亲属的CGT率显著高于男性一级亲属(59% vs 21%,P < 0.001)。
  • HBOC患者报告的一级亲属CGT率显著高于LS患者(49% vs 33%,P = 0.02)。

核心结论

  • HBOC和LS突变携带者的结果告知率较高,但报告的一级亲属CGT率较低。
  • 性别和突变特异性障碍阻碍了患者家属接受CGT。
  • 未来研究应实施材料以解决这些障碍并提高CGT率。

研究设计与样本

  • 对2011至2016年间在某学术机构经胚系基因检测确诊的HBOC或LS患者进行问卷调查,评估结果告知、亲属检测情况及对教育材料的看法。
  • 103名突变携带者同意参与,其中64名(63%)在收到基因检测结果平均38个月后完成调查。
  • 参与者平均年龄53岁,31名(48%)有癌症诊断。
  • 医疗记录和家系图提供了总亲属和一级亲属的数量。

主要发现

  • 86%的参与者对分享健康信息感到极其或非常自在。
  • 参与者向87%的一级亲属告知了检测结果,但报告仅40%的一级亲属接受了检测。
  • 女性一级亲属的CGT率显著高于男性一级亲属(59% vs 21%,P < 0.001)。
  • HBOC患者报告的一级亲属CGT率显著高于LS患者(49% vs 33%,P = 0.02)。
  • 参与者未认定任何一种教育媒介在告知结果方面比其他媒介更有帮助。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cascade genetic testing (CGT) of hereditary breast and ovarian cancer (HBOC) or Lynch Syndrome (LS) patients' relatives offers opportunities to prevent cancer, but CGT rates are not well described. We aimed to measure reported disclosure of genetic testing results and CGT rates in these families and evaluate patients' views of educational media. METHODS: Patients with HBOC or LS identified from germline genetic testing at an academic institution between 2011 and 2016 were surveyed regarding disclosure, testing among relatives, and perceptions of educational materials. Medical records and pedigrees provided numbers of total and first-degree relatives. RESULTS: Of 103 mutation carriers consented, 64 (63%) completed the survey an average of 38 months after receiving genetic testing results. Participants' mean age was 53 years, and thirty-one (48%) had a cancer diagnosis. The majority (86%) felt extremely or very comfortable sharing health information. Participants disclosed results to 87% of first-degree relatives, but reported that only 40% of first-degree relatives underwent testing. First-degree female relatives had significantly higher CGT rates than first-degree male relatives (59% versus 21%, P < 0.001). Participants with HBOC reported higher CGT rates than those with LS (49% versus 33%, P = 0.02). Participants did not identify any one educational medium as more helpful than the others for disclosing results. CONCLUSION: Disclosure rates are high among HBOC and LS mutation carriers, but reported CGT rates are low. Gender- and mutation-specific barriers prevent patients' family members from undergoing CGT. Future studies should implement materials to address these barriers and improve CGT rates.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Griffin NE, Buchanan TR, Smith SH, et al. Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention. Gynecol Oncol. 2019. PMID: 31780235. doi:10.1016/j.ygyno.2019.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。